Best Hospitals for Pulmonary Fibrosis in Delhi NCR, India

Pulmonary fibrosis — most critically in its idiopathic form (IPF) — is a progressive, irreversible scarring of lung parenchyma driven by aberrant epithelial injury-repair cycles, fibroblast proliferation, and excess extracellular matrix deposition. As fibrosis advances, alveolar architecture is destroyed, gas exchange efficiency falls, and patients develop exertional hypoxemia, a dry non-productive cough, and progressively restrictive ventilatory physiology. Median survival from diagnosis without treatment is historically 3–5 years, though disease trajectory varies considerably — a minority follow a slowly progressive course, while others experience acute exacerbations that carry a 50–80% in-hospital mortality.

• CONFIRMED IPF DIAGNOSIS: Multidisciplinary ILD board consensus based on HRCT UIP pattern (± surgical lung biopsy via VATS) after exclusion of secondary causes (connective tissue disease, drug toxicity, hypersensitivity pneumonitis)
• ANTIFIBROTIC THERAPY CANDIDATES: FVC ≥50% predicted, DLCO ≥30% predicted, confirmed UIP/probable UIP on HRCT, NYHA/MRC dyspnea grade II–III, absence of advanced hepatic impairment (nintedanib) or severe photosensitivity contraindication (pirfenidone)
• TRANSPLANT EVALUATION CANDIDATES: Progressive disease despite ≥6 months of antifibrotic therapy, FVC <80% predicted with ≥10% relative decline over 12 months, DLCO <40% predicted, 6-minute walk test desaturation below SpO₂ 88%, or acute exacerbation requiring hospitalization
• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: HRCT chest (thin-slice ≤1.5 mm), full pulmonary function tests (spirometry, plethysmography, DLCO), 6-minute walk test with oximetry, echocardiography (to assess pulmonary hypertension — a key modifier of transplant candidacy), CT pulmonary angiography or V/Q scan (to exclude chronic thromboembolic disease), standard metabolic panel, LFTs, renal function, and ANA/RF/anti-CCP/anti-Scl70 autoimmune panel
• FOR TRANSPLANT EVALUATION: Right heart catheterization (mPAP, PAWP, PVR), coronary angiography (if age >50 or cardiovascular risk factors), bone densitometry, upper GI endoscopy, age-appropriate cancer screening, psychosocial assessment, and body composition/nutritional assessment (BMI <16 or >35 kg/m² are relative contraindications)
• +2 more

ANTIFIBROTIC PHARMACOTHERAPY Nintedanib (Ofev®): A triple tyrosine kinase inhibitor administered orally at 150 mg twice daily with food. It inhibits PDGFR-α/β, FGFR-1/2/3, and VEGFR-1/2/3 — receptors that mediate fibroblast proliferation, differentiation, and migration. In the INPULSIS trials, nintedanib reduced annual FVC decline by 50% (approximately 50 mL/year vs. 200 mL/year on placebo). Key adverse effects include diarrhea (60–65% of patients; managed with loperamide and dose reduction to 100 mg BID), nausea, and elevated hepatic transaminases requiring monthly LFT monitoring in the first 3 months.

Pirfenidone (Esbriet®): An oral antifibrotic with anti-inflammatory and antioxidant properties acting primarily through TGF-β1 pathway suppression, dosed at 2,403 mg/day in three divided doses after titration. ASCEND and CAPACITY trials demonstrated a 47% reduction in FVC decline versus placebo. Key adverse effects include photosensitivity (mandatory daily broad-spectrum SPF 50+ sunscreen), gastrointestinal intolerance, and fatigue. Dose titration over 3 weeks reduces GI side effects.

Combination therapy (nintedanib + pirfenidone) is under investigation; current evidence from the INJOURNEY trial suggests pharmacokinetic compatibility and additive tolerability — specialists at partner centers will individualize based on the patient's tolerance profile.

OXYGEN THERAPY & PULMONARY REHABILITATION Ambulatory long-term oxygen therapy (LTOT) is initiated when resting SpO₂ ≤88% or exercise-induced desaturation is documented. Supervised pulmonary rehabilitation programs — combining endurance and resistance exercise with respiratory physiotherapy and nutritional counseling — improve 6MWT distance by 30–50 meters and patient-reported quality of life scores, though they do not alter disease trajectory. GAF Healthcare partner centers offer structured 2–4 week intensive inpatient or day-program pulmonary rehabilitation modules for traveling patients.

PHASE 1 — PRE-ARRIVAL COORDINATION (2–4 weeks before travel) GAF Healthcare's medical coordinators review all existing diagnostic records (HRCT, PFTs, bronchoscopy/biopsy reports, echocardiography) via a secure digital portal. The in-house medical team prepares a provisional treatment pathway — antifibrotic initiation vs. transplant evaluation — and selects the appropriate partner center. The patient receives a pre-travel checklist specifying required investigations to be completed at home to avoid duplication and unnecessary cost. e-Medical visa (India) or UAE entry visa documentation is prepared in parallel.

PHASE 2 — ARRIVAL & INITIAL ASSESSMENT (Days 1–3) The patient is received at the airport by a GAF Healthcare coordinator and transferred directly to the partner hospital. On Day 1, pulmonology admission is completed, baseline vitals, resting and ambulatory SpO₂, and 6MWT are recorded. Day 2 involves confirmatory investigations: thin-slice HRCT chest review by an ILD-specialist radiologist, full PFTs with bronchodilator response, echocardiography, and a comprehensive laboratory panel including LFTs, renal function, CBC, BNP/NT-proBNP, and an updated autoimmune screen. Day 3: multidisciplinary ILD board review, treatment decision communicated to patient and family with written informed consent.

PHASE 3A — ANTIFIBROTIC THERAPY PATHWAY (Days 4–14) The chosen antifibrotic agent is initiated under supervision. For pirfenidone, a 2-week in-country titration schedule (801 mg TID × 1 week → 1,602 mg TID × 1 week → 2,403 mg TID thereafter) allows assessment of GI tolerance and photosensitivity. For nintedanib, full-dose 150 mg BID initiation with LFT checks at Day 7 and Day 14. Pulmonary rehabilitation sessions begin on Day 4–5. Supplemental oxygen titration, GERD management, and sleep study (if indicated) are conducted during this phase. Milestone: Patient achieves therapeutic antifibrotic dose, tolerability confirmed, rehabilitation baseline established. Fit-to-fly assessment at Day 14–21 based on SpO₂ stability on ambulatory oxygen (if required), HRCT stability, and confirmed outpatient pharmacy access in home country.